Join to View Full Profile
530 E 74th StNew York, NY 10021
Phone+1 212-639-2000
Dr. Chin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kuo-Kai Chin is an oncology specialist based in New York, NY, currently serving as Assistant Attending L1 at Memorial Sloan Kettering Cancer Center. Dr. Chin completed a residency in Internal Medicine at Mass General Brigham/Brigham and Women's Hospital from 2019 to 2022, followed by a fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center from 2022 to 2025. A graduate of Stanford University School of Medicine, Dr. Chin has contributed to multiple publications in the field of acute myeloid leukemia and oncology, addressing topics such as treatment cost reduction and novel strategies for overcoming drug resistance. Dr. Chin's work has been published in prominent journals including Leukemia, Blood Advances, Cancer, and JAMA Oncology.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2022 - 2025
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2019 - 2022
Stanford University School of MedicineClass of 2019
Certifications & Licensure
NJ State Medical License 2025 - 2027
NY State Medical License 2022 - 2027
MA State Medical License 2019 - 2022
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia.Kuo-Kai Chin, Maher Abdul-Hay, Mihir Shukla, Mark B Geyer, Roni Tamari
Leukemia. 2026-04-10 - 1 citationsOutcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.Kuo-Kai Chin, Brian J Ball, Yasmin Abaza, Jessica K Altman, Rahul K Thakur
Blood Advances. 2026-03-10 - 1 citationsCurative strategies for high-risk acute promyelocytic leukemia.Kuo-Kai Chin, Martin S Tallman
Current Opinion in Oncology. 2025-11-01
Professional Memberships
- Gold Humanism Honor SocietyMember
Other Languages
- Chinese (Mandarin), Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
